Growth Metrics

Boston Scientific (BSX) Non-Current Deferred Tax Liability (2016 - 2026)

Boston Scientific's Non-Current Deferred Tax Liability history spans 18 years, with the latest figure at $219.0 million for Q1 2026.

  • On a quarterly basis, Non-Current Deferred Tax Liability rose 38.61% to $219.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $219.0 million, a 38.61% increase, with the full-year FY2025 number at $220.0 million, down 0.9% from a year prior.
  • Non-Current Deferred Tax Liability hit $219.0 million in Q1 2026 for Boston Scientific, roughly flat from $220.0 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for BSX hit a ceiling of $278.0 million in Q3 2022 and a floor of $91.0 million in Q3 2023.
  • Historically, Non-Current Deferred Tax Liability has averaged $188.6 million across 5 years, with a median of $210.0 million in 2023.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: soared 130.43% in 2022 and later plummeted 67.27% in 2023.
  • Tracing BSX's Non-Current Deferred Tax Liability over 5 years: stood at $144.0 million in 2022, then dropped by 6.94% to $134.0 million in 2023, then surged by 65.67% to $222.0 million in 2024, then decreased by 0.9% to $220.0 million in 2025, then dropped by 0.45% to $219.0 million in 2026.
  • Business Quant data shows Non-Current Deferred Tax Liability for BSX at $219.0 million in Q1 2026, $220.0 million in Q4 2025, and $242.0 million in Q3 2025.